Nexvet Biopharma (NVET) Misses Q3 EPS by 3c

Nexvet Biopharma (NASDAQ: NVET) reported Q3 EPS of ($0.44), $0.03 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Nexvet Biopharma (NVET) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Oracle’s Ellison cancels plan to sell up to 50 mln shares
• Piper Sandler picks Q2 Holdings as preferred stock in payments coverage